1 The airway and pulmonary vascular effects of adrenomedullin were studied in the guinea-pig isolated trachea, main bronchi and pulmonary artery in vitro and compared to the effects of calcitonin generelated peptide (CGRP).2 In tracheal rings, CGRP (1 nM to 1 gM) potentiated the cholinergic contractions induced by electrical field stimulation (EFS) at 5 Hz in a concentration-dependent manner. At a concentration of 1 gM, CGRP slightly decreased the responses to log EFS frequency, producing 50% of the maximum contraction from a control value of 0.77+0.10 Hz to 0.54+0.05 Hz without a significant effect on the concentration-response curves to acetylcholine (ACh). In contrast, adrenomedullin (1 nM to 1 gM) did not alter either EFS-induced cholinergic or ACh-induced contractions. 3 In bronchial strips, CGRP (1 nm to 1 pM) slightly reduced both the non-adrenergic non-cholinergic (NANC) contraction induced by EFS at 10 Hz and the substance P (1 gM)-induced contraction in a concentration-dependent manner, whereas adrenomedullin (1 nM to 1 pM) was without effect.4 Neither CGRP (1 gM) nor adrenomedullin (1 gM) altered NANC relaxation induced by EFS at 5 Hz in tracheal rings precontracted with histamine (10 gM). Adrenomedullin (1 nm to 1 gM) and CGRP (1 nM to 1 pM) induced a concentration-dependent relaxation of the histamine (10 pM)-and prostaglandin F2a (10 gM)-precontracted pulmonary arterial rings with intact endothelium with a similar potency.6 Neither removal of the endothelium nor NG-nitro-L-arginine methyl ester (100 pM) altered the vasorelaxant effects of adrenomedullin (1 nM to 1 pM) and CGRP (1 nM to 1 gM). 7 The putative CGRP receptor antagonist, CGRP8-37 (1 MM to 10 gM) concentration-dependently attenuated the CGRP (3 nM to 30 nM)-induced vasorelaxant actions, whereas it had no effect on the relaxation of vessel rings induced by adrenomedullin (3 nM to 30 nM). 8 These results suggest that adrenomedullin is a potent vasodilator of the pulmonary artery without any bronchomotor effect in the guinea-pig lung, and that the vasorelaxant actions of adrenomedullin are not mediated via the activation of CGRP1 receptors.